• AbbVie (NYSE:ABBV) reported positive Phase 3b/4 results from the SELECT-SWITCH trial, showing RINVOQ outperformed HUMIRA in rheumatoid arthritis patients who had already tried a TNF inhibitor.
• The study provided the first direct head to head evidence in this specific switch setting, with higher remission rates for RINVOQ and no new safety findings versus HUMIRA.
• AbbVie also reached a development milestone with EvolveImmune Therapeutics related to an oncology program, adding to its solid tumor pipeline.

AbbVie enters this news cycle with its shares at $197.69 and a mixed return profile, including a 45.2% gain over 3 years and 109.4% over 5 years, while return_ytd is a 13.8% decline. In that context, fresh clinical data and pipeline milestones matter for how investors view the durability of its immunology and oncology franchises.

For readers tracking NYSE:ABBV, the RINVOQ versus HUMIRA data speaks directly to how AbbVie might compete as immunology patents age and treatment choices broaden. The added oncology milestone with EvolveImmune indicates management is continuing to build out exposure to solid tumors, which many investors watch as part of AbbVie’s longer term strategic positioning.

Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.

Quick Assessment

• ✅ Price vs Analyst Target: At US$197.69 versus a US$249.27 analyst target, the price sits about 26% below consensus.
• ✅ Simply Wall St Valuation: The shares are described as trading 50.6% below an estimated fair value, which screens as undervalued.
• ❌ Recent Momentum: The 30 day return of roughly 5.6% decline shows recent weakness despite the positive news.

There is only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's company report for the latest analysis of AbbVie's Fair Value.

Key Considerations

• 📊 The RINVOQ outperformance over HUMIRA in a direct switch setting highlights how AbbVie might retain patients as treatment options widen.
• 📊 It may be useful to watch uptake data for RINVOQ, progress on the EvolveImmune oncology program, the current 83.5x P/E, and the gap to the US$249.27 price target.
• ⚠️ Key flagged risks include dividend coverage, insider selling, debt levels and one off items affecting earnings quality.

Dig Deeper

For the full picture, including more risks and potential rewards, check out the complete AbbVie analysis. Alternatively, you can visit the community page for AbbVie to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.